519 related articles for article (PubMed ID: 32601780)
1. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
[TBL] [Abstract][Full Text] [Related]
2. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
[TBL] [Abstract][Full Text] [Related]
3. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
[TBL] [Abstract][Full Text] [Related]
4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
5. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
7. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Wang HY; Cai ZX; Yin D; Yang YJ; Song WH; Dou KF
Am J Cardiol; 2021 Mar; 142():14-24. PubMed ID: 33285091
[TBL] [Abstract][Full Text] [Related]
8. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
[TBL] [Abstract][Full Text] [Related]
10. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI.
Wang HY; Gao RL; Xu B; Yang YJ; Yin D; Wang Y; Dou KF
Platelets; 2021 May; 32(4):533-541. PubMed ID: 32498587
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
14. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
[TBL] [Abstract][Full Text] [Related]
15. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines.
Ueki Y; Karagiannis A; Zanchin C; Zanchin T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Otsuka T; Hunziker L; Heg D; Moschovitis A; Seiler C; Billinger M; Pilgrim T; Valgimigli M; Windecker S; Räber L
JACC Cardiovasc Interv; 2019 May; 12(9):820-830. PubMed ID: 30981574
[TBL] [Abstract][Full Text] [Related]
16. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
17. [Benefits and risks of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent in patients with stable coronary artery disease and diabetes].
Cui KY; Yin D; Feng L; Zhu CG; Song WH; Wang HJ; Jia L; Zhang D; Yuan S; Wu SY; He JN; Qiao Z; Dou KF
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):458-465. PubMed ID: 35589594
[No Abstract] [Full Text] [Related]
18. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
[TBL] [Abstract][Full Text] [Related]
19. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
[TBL] [Abstract][Full Text] [Related]
20. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.
Lee OH; Kim BK; Hong SJ; Kim S; Ahn CM; Shin DH; Kim JS; Kang TS; Ko YG; Choi D; Hong MK; Jang Y
Yonsei Med J; 2020 Jul; 61(7):597-605. PubMed ID: 32608203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
